Schizophrenia Clinical Trials

263 recruiting

Understanding Schizophrenia Clinical Trials

Every antipsychotic medication used to treat schizophrenia today, from first-generation drugs like chlorpromazine to newer options like cariprazine (Vraylar) and lumateperone (Caplyta), was developed through clinical trials. In 2024, the FDA approved cobenfy (xanomeline-trospium), the first truly novel mechanism for schizophrenia treatment in decades, targeting muscarinic receptors rather than dopamine, a breakthrough that only became possible through years of clinical trial research. For the approximately 2.8 million adults in the United States living with schizophrenia, ongoing trials are exploring treatments that aim to address not just psychotic symptoms but also the cognitive and social difficulties that current medications often leave untreated.

Why Consider a Clinical Trial?

Current antipsychotic medications primarily target the positive symptoms of schizophrenia, such as hallucinations and delusions, but many people continue to struggle with negative symptoms like social withdrawal, flat affect, and lack of motivation, as well as cognitive difficulties affecting memory, attention, and decision-making. These unaddressed symptoms are often the biggest barriers to living independently and maintaining employment. Clinical trials are testing treatments specifically designed to target these gaps, including cognitive enhancers, glutamate-modulating drugs, and novel anti-inflammatory approaches. Many people with schizophrenia also experience significant side effects from current medications, including weight gain, metabolic syndrome, and movement disorders. Newer agents being studied in clinical trials aim to provide symptom control with a more favorable side effect profile. Participating in a trial also means receiving care from a specialized research team with deep expertise in schizophrenia, often at major academic medical centers, with consistent and thorough monitoring throughout the study period.

Frequently Asked Questions

Common questions about Schizophrenia clinical trials

Yes, many trials allow participants to continue their current medication. Some studies test add-on treatments that supplement your existing antipsychotic, while others may require a supervised medication change. The research team will explain exactly what is required and will not make any changes without your consent.

Yes, cognitive impairment is a major focus of current schizophrenia research. Trials are testing pro-cognitive medications, computerized cognitive training programs, and combination approaches. These studies typically measure improvements in memory, attention, and problem-solving using standardized neuropsychological tests.

All schizophrenia trials have safety protocols for symptom worsening. If your symptoms significantly worsen, the research team can provide rescue medication, adjust your treatment, or withdraw you from the study with a safe transition plan back to standard care. Your wellbeing always takes priority over the research protocol.

Most schizophrenia trials welcome caregiver involvement. Family members can attend study visits, help with transportation, and assist with medication adherence. Some studies specifically include caregiver assessments as part of the outcome measures. The research team will work with you and your support network.

Most schizophrenia trials are conducted on an outpatient basis, meaning you attend scheduled visits at the research site but live at home. Some acute-phase trials may begin with a brief inpatient stabilization period. The study design will be clearly explained before you consent to participate.

Showing 120 of 263 trials

Recruiting
Phase 1Phase 2

Tolerability of MDMA in Schizophrenia

Schizophrenia
Anya Bershad, MD, PhD20 enrolled1 locationNCT05770375
Recruiting
Phase 1Phase 2

Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia

SchizophreniaSchizo Affective Disorder
Vishwajit Nimgaonkar, MD PhD160 enrolled1 locationNCT03794076
Recruiting
Not Applicable

Cerebellar Stimulation and Cognitive Control

DepressionParkinson DiseaseSchizophrenia+2 more
Krystal Parker, PhD200 enrolled1 locationNCT03217110
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia

Schizophrenia
Bristol-Myers Squibb250 enrolled55 locationsNCT06882785
Recruiting
Not Applicable

Cerebellar Modulation of Cognition in Psychosis

SchizophreniaPsychosisSchizoaffective Disorder+1 more
Mclean Hospital95 enrolled2 locationsNCT06107764
Recruiting

Biomarker Research on Ultra-High-Field MRI Combined With Visual Perception Assessment in the Diagnosis and Treatment Outcomes of Severe Mental Disorders

SchizophreniaMajor Depressive Disorder (MDD)Bipolar Disorder+1 more
Second Affiliated Hospital, School of Medicine, Zhejiang University320 enrolled1 locationNCT07479758
Recruiting
Phase 3

Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients

Schizophrenia
Central South University400 enrolled8 locationsNCT07045142
Recruiting

Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

Schizophrenia
Bristol-Myers Squibb300 enrolled17 locationsNCT07101094
Recruiting
Not Applicable

Non-invasive Brain Stimulation Using Tdcs of the Third (of Many) Visual Pathways

Schizo Affective DisorderSCHIZOPHRENIA 1 (Disorder)
Nathan Kline Institute for Psychiatric Research120 enrolled1 locationNCT07469384
Recruiting
Phase 4

A Study to Evaluate the Effect of KarXT on Urological Safety

Schizophrenia
Bristol-Myers Squibb60 enrolled14 locationsNCT07221877
Recruiting
Not Applicable

Time and Virtual Reality in Schizophrenia and Bipolar Disorder

SchizophreniaBipolar Disorder
Institut National de la Santé Et de la Recherche Médicale, France120 enrolled1 locationNCT04432116
Recruiting
Phase 3

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

Schizophrenia
Karuna Therapeutics280 enrolled175 locationsNCT05304767
Recruiting
Not Applicable

Feasibility, Acceptability, and Preliminary Efficacy of Yoga-based Group Intervention for Outpatients With Schizophrenia Spectrum Disorders

Schizophrenia Spectrum DisordersPsychotic Disorders
Charite University, Berlin, Germany60 enrolled1 locationNCT07455929
Recruiting
Not Applicable

Decision-Making in Schizophrenia: A Combined Neuroimaging and Experience Sampling Study

SchizophreniaControl SubjectsSchizoaffective Disorder
Rutgers, The State University of New Jersey74 enrolled1 locationNCT06745479
Recruiting

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

SchizophreniaSchizoaffective DisorderDelusional Disorder+4 more
Beth Israel Deaconess Medical Center320 enrolled6 locationsNCT06740383
Recruiting
Phase 2

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

Schizophrenia
MapLight Therapeutics300 enrolled25 locationsNCT07038876
Recruiting
Not Applicable

Deep Brain Stimulation in Treatment Resistant Schizophrenia

Treatment-resistant Schizophrenia
Johns Hopkins University6 enrolled1 locationNCT02361554
Recruiting

Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

Schizophrenia
Bristol-Myers Squibb1,500 enrolled32 locationsNCT07379827
Recruiting
Not Applicable

Prebiotic Treatment in People With Schizophrenia

SchizophreniaSchizoaffective Disorder
University of Maryland, Baltimore60 enrolled1 locationNCT05527210
Recruiting
Phase 3

NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

Schizophrenia
Neurocrine Biosciences284 enrolled21 locationsNCT06963034